Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A414BN | ISIN: US47010C8881 | Ticker-Symbol: 1JA0
NASDAQ
24.04.25
21:55 Uhr
8,010 US-Dollar
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
JAGUAR HEALTH INC Chart 1 Jahr
5-Tage-Chart
JAGUAR HEALTH INC 5-Tage-Chart

Aktuelle News zur JAGUAR HEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SaJaguar Health, Inc. - 8-K, Current Report3
17.04.Jaguar Health, Inc.: Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress189Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and...
► Artikel lesen
15.04.Jaguar Health files to sell 1.29M shares of common stock for holders11
15.04.Jaguar Health, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
15.04.Jaguar Health, Inc. - 10-K/A, Annual Report2
15.04.Jaguar Health bespricht Brustkrebsbehandlung mit FDA21
JAGUAR HEALTH Aktie jetzt für 0€ handeln
15.04.Jaguar Health to discuss breast cancer treatment with FDA2
15.04.Jaguar Health, Inc.: Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer Annual Meeting229The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December...
► Artikel lesen
08.04.Jaguar Health, Inc.: Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product280Gelclair® is the company's third commercialized prescription productOral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant...
► Artikel lesen
04.04.Jaguar Health, Inc. - 8-K, Current Report3
04.04.Jaguar Health, Inc.: Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635335SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 restricted...
► Artikel lesen
02.04.Jaguar Health zeigt Fortschritte trotz Verlusten32
01.04.Jaguar Health completes $3.4 million private placement2
01.04.Jaguar Health schließt private Platzierung in Höhe von 3,4 Millionen US-Dollar ab4
01.04.Jaguar Health, Inc.: Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules306SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement.Jaguar's...
► Artikel lesen
31.03.Jaguar Health outlines key Q2 2025 catalysts for crofelemer programs7
31.03.Jaguar Health GAAP EPS of -$5.23, revenue of $11.69M4
31.03.Jaguar Health, Inc.: Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023225The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus...
► Artikel lesen
31.03.Jaguar Health, Inc. - 10-K, Annual Report6
30.03.Jaguar Health: Umsatzwachstum trotz Verlusten im Fokus6
Seite:  Weiter >>
118 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1